Biosimilar Clinical Development Streamlined
400 Trillion Won in Patent-Expired Drugs Expected Over the Next Decade

The global biosimilar market is entering a period of opportunity known as the "Golden Decade."


According to data released on March 12 by the Bioeconomy Research Center of the Korea Biotechnology Industry Organization, patents for branded biopharmaceuticals worth more than 300 billion dollars (approximately 44.3 trillion won) are set to expire over the next ten years. This is expected to create significant opportunities for biosimilar companies to expand their market presence.

400 Trillion Won Patent Cliff Approaches: Biosimilars Enter a "Golden Decade" of Market Disruption View original image

Sandoz, a Swiss company that is a global leader in the biosimilar market, anticipates a sharp increase in the value of "Loss of Exclusivity (LoE)" from this year through 2036 and is preparing to secure its market position. Based on Sandoz's projections, the LoE value is expected to peak at 54 billion dollars (about 7.9 trillion won) in 2028, 53 billion dollars (about 7.8 trillion won) in 2031, and 70 billion dollars (about 10.3 trillion won) in 2033. Richard Saynor, CEO of Sandoz, stated, "We aim to capture 59% of the entire biosimilar market over the next ten years through the 27 biosimilar products currently under development."


Sandoz has termed this period of patent expirations the "Golden Decade" and has established a dedicated organization focused on biosimilars. The company created a new "Biosimilar Development, Manufacturing, and Supply Division," appointing Dr. Armin Metzger as its head to accelerate vertical integration. Sandoz has also announced streamlined clinical development plans for three high-value medicines: Keytruda (pembrolizumab), Ocrevus (ocrelizumab), and Opdivo (nivolumab), signaling an aggressive strategy. Last year, Sandoz recorded sales of 11.1 billion dollars (approximately 1.6417 trillion won), with biosimilar revenue rising 13% year-on-year to 3.3 billion dollars (about 488.1 billion won).


Domestic companies competing with Sandoz are also significantly expanding the development of new biosimilars. At the J.P. Morgan Healthcare Conference in January, Celltrion unveiled a roadmap to increase its biosimilar product portfolio from the current 11 to 41 by 2038. Seojin Seok, Head of Business Operations at Celltrion, projected that the size of the addressable global market would exceed 400 trillion won by 2038, more than four times last year's level, due to portfolio expansion. Kim Kyungah, CEO of Samsung Bioepis, also stated, "We will proactively expand our biosimilar portfolio to a total of 20 by 2030," adding, "We are currently developing biosimilars for seven blockbuster drugs, including Keytruda, Dupixent, and Enhertu."



The expiration of original drug patents, along with regulatory agencies' efforts to streamline clinical trials, is also favorable for biosimilar companies. The U.S. Food and Drug Administration (FDA) recently released a draft industry guidance aimed at simplifying biosimilar development. The guidance recommends significant streamlining of clinical pharmacokinetic (PK) studies when there is sufficient scientific justification. The FDA analyzed that these measures could reduce companies' PK research costs by up to 50% (an average of about 20 million dollars, or approximately 2.95 billion won). Additionally, the agency clarified the criteria for using clinical data from outside the United States and eliminated the requirement for complex three-arm PK studies, greatly lowering development barriers. If the requirements for comparative efficacy studies (CES) are fully reduced this year, the development timeline could be shortened by one to three years, and costs could be further reduced by about 24 million dollars. These changes reflect policy efforts to improve patient access to treatment and alleviate the burden of medical expenses.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing